Intra-Cellular Therapies, Inc.

ITCI

US46116X1019

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-13 pm EDT			5-day change	1st Jan Change
66.32 ^USD	+2.09%		-6.60%	-7.40%

May. 07	Sector Update: Health Care Stocks Steady Pre-Bell Tuesday	MT
May. 07	Transcript : Intra-Cellular Therapies, Inc., Q1 2024 Earnings Call, May 07, 2024

INTRA-CELLULAR THERAPIES, INC. : Financial Statements and Exhibits (form 8-K)

January 05, 2022 at 05:00 pm EST

ITEM 9.01 Financial Statements and Exhibits.




(d)  Exhibits



Exhibit
Number       Description

10.1           Supply Agreement dated as of January 4, 2017 by and between
             Siegfried Evionnaz SA and ITI Limited

104          Cover Page Interactive Data File (embedded within the Inline XBRL
             document)

--------------------------------------------------------------------------------

Latest news about Intra-Cellular Therapies, Inc.

Sector Update: Health Care Stocks Steady Pre-Bell Tuesday	May. 07	MT
Transcript : Intra-Cellular Therapies, Inc., Q1 2024 Earnings Call, May 07, 2024	May. 07
Intra-Cellular Therapies' Q1 Net Loss Narrows, Net Total Revenue Rises	May. 07	MT
Earnings Flash (ITCI) INTRA-CELLULAR THERAPIES Posts Q1 Revenue $144.9M	May. 07	MT
Earnings Flash (ITCI) INTRA-CELLULAR THERAPIES Posts Q1 Revenue $144.9M	May. 07	MT
Intra-Cellular Therapies, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07	CI
Intra-Cellular Therapies, Inc. Reiterates Earnings Guidance for the Full Year 2024	May. 07	CI
Canaccord Genuity Raises Intra-Cellular Therapies' Price Target to $107 From $100, Maintains Buy Rating	Apr. 23	MT
Needham & Co Adjusts Intra-Cellular Therapies Price Target to $90 From $82, Maintains Buy Rating	Apr. 22	MT
Mizuho Raises Price Target on Intra-Cellular Therapies to $96 From $82, Keeps Buy Rating	Apr. 22	MT
Intra-Cellular Therapies Prices $500 Million Stock Offering	Apr. 18	MT
Goldman Sachs Adjusts Price Target on Intra-Cellular Therapies to $77 From $67, Maintains Neutral Rating	Apr. 17	MT
BofA Securities Adjusts Price Target on Intra-Cellular Therapies to $91 From $82, Maintains Buy Rating	Apr. 17	MT
Baird Adjusts Price Target on Intra-Cellular Therapies to $103 From $83, Maintains Outperform Rating	Apr. 17	MT
TD Cowen Adjusts Price Target on Intra-Cellular Therapies to $90 From $80, Maintains Buy Rating	Apr. 17	MT
Morgan Stanley Lifts Price Target on Intra-Cellular Therapies to $92 From $85, Says Study 501 Exceeds Its Highest Expectations; Overweight Kept	Apr. 17	MT
Intra-Cellular Therapies Launches $500 Million Public Offering of Stock; Shares Edge Lower in Late Trade	Apr. 16	MT
Sector Update: Health Care Stocks Higher Late Afternoon	Apr. 16	MT
Top Midday Gainers	Apr. 16	MT
US Stocks Lacking Direction Prior to Powell Remarks, Investors Looking for Signs of Future Rate Cuts by Federal Reserve	Apr. 16	MT
Intra-Cellular Therapies Stock Jumps After Major Depressive Disorder Treatment Study Shows Positive Results	Apr. 16	MT
Transcript : Intra-Cellular Therapies, Inc. - Special Call	Apr. 16
Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder	Apr. 16	CI
Intra-Cellular Therapies CFO Hineline Retiring, Promotes Halstead to President	Mar. 19	MT
Intra-Cellular Therapies, Inc. Announces Executive Changes	Mar. 19	CI

Chart Intra-Cellular Therapies, Inc.

Duration

Period

More charts

Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders. The Company leverages intracellular approach to develop treatments for people living with complex psychiatric and neurologic diseases. The Companyâs product, CAPLYTA (lumateperone), is an oral, once daily atypical antipsychotic approved in adults for the treatment of schizophrenia and the treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate. Its pipeline includes several product candidates in clinical development and additional product candidates in non-clinical testing, such as ITI-1284-ODT-SL program, Phosphodiesterase type I inhibitor (PDE1) program, ITI-333 program, and ITI-1500 Non-Hallucinogenic Psychedelic program. ITI-1284 is a deuterated form of lumateperone, a new chemical entity.

Sector

Pharmaceuticals

Calendar

10:00am - RBC Capital Markets Global Healthcare Conference

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Intra-Cellular Therapies, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

66.32 USD

Average target price

90.6 USD

Spread / Average Target

+36.61%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
INTRA-CELLULAR THERAPIES, INC.	-7.40%	7B
CSL LIMITED	-2.47%	89.37B
SAMSUNG BIOLOGICS CO.,LTD.	+2.76%	40.65B
BIOGEN INC.	-12.92%	32.81B
UCB	+53.61%	25B
BIOMARIN PHARMACEUTICAL INC.	-16.51%	15.29B
INCYTE CORPORATION	-8.27%	12.93B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-42.60%	11.61B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-12.82%	11.49B
SWEDISH ORPHAN BIOVITRUM AB	+3.67%	8.98B

Biopharmaceuticals